| Steroid and Antibiotic Treatment are associated with diverse Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group. |
|
|
| Oncol Res Treat 47(suppl 2): 317 (P1106) |
|
2024 |
| doi.org/10.1159/000540557 |
|
|
| Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy a pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group |
|
|
| Z Gastroenterol 62(09): 711-2 |
|
2024 |
| doi.org/10.1055/s-0044-1789880 |
|
|
| S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial. |
Stocker G |
Haag GM |
|
|
2023 |
|
Ösophagus-/Magenkarzinome
|
MATEO |
AIO-YMO-0111 |
| doi.org/10.1016/j.esmoop.2023.101572 |
|
|
| Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial |
Tintelnot J |
Binder M |
| J Clin Oncol 41 (16_suppl): 4026 |
Abstract |
2023 |
|
Ösophagus-/Magenkarzinome
|
INTEGA |
AIO-STO-0217 |
| doi.org/10.1200/JCO.2023.41.16_suppl.4026 |
|
|
| A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415). |
Gruenwald V. |
Viktor Grünwald |
| Ann Oncol 34 (Supplement 2, S1331-2, LBA90) |
Abstract |
2023 |
|
Weichteilsarkome
|
MEDISARC |
AIO-STS-0415 |
| doi.org/10.1016/j.annonc.2023.10.092 |
|
|
| Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC. |
|
|
| Ann Oncol 34 (Supplement 2, S1207-8, 2372P) |
|
2023 |
|
Urothelkarzinom
|
|
|
| doi.org/10.1016/j.annonc.2023.09.1021 |
|
|
| Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. |
|
|
| Lancet Oncol 24 (4): 347-59 |
|
2023 |
|
Urothelkarzinom
|
|
|
| www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00053-0/fulltext |
|
|
| Testing for and frequency of EGFR and ALK alterations in patients with early and locally advanced non-small cell lung cancer in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315). |
|
|
| Oncol Res Treat 46 (suppl.5): 10-11 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1159/000533576 |
|
|
| SCLC patients treated with vs without prophylactic cranial irradiation in palliative setting after systemic treatment with checkpoint inhibitors – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-) Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). |
|
|
| Oncol Res Treat 46 (suppl.5): 7-8 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1159/000533576 |
|
|
| DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC). |
|
|
| Ann Oncol 34 (Supplement 2, S820, 1442P) |
Abstract |
2023 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.annonc.2023.09.2473 |
|
|
